These findings outline the importance of AKR1B10 in the BM resistance to tumor therapy via a way of metabolic reprogramming and epigenetic modification, providing new strategies to overcome chemotherapy resistance in lung cancer BM. This evidence concerns the gene AKR1B10 and lung carcinoma.